Modality
Multispecific
MOA
GLP-1/GIP
Target
JAK1
Pathway
NF-κB
SLEADHD
Development Pipeline
Preclinical
Feb 2024
→ Sep 2029
PreclinicalCurrent
NCT05042040
1,998 pts·SLE
2024-02→2029-09·Active
1,998 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-113.4y awayInterim· SLE
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2029-09-11 · 3.4y away
SLE
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05042040 | Preclinical | SLE | Active | 1998 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| MLY-3531 | Mineralys | NDA/BLA | JAK1 |